You are here: Home » Current Affairs » Coronavirus » News
Business Standard

WHO rejects SII's proposal for extension of Covishield's shelf life: Report

The WHO has rejected Serum Institute of India's proposal seeking extension of the shelf life of Oxford-AstraZeneca Covid-19 vaccine, Covishield, from six to nine months, citing insufficient data

Topics
Serum Institute of India | WHO | Coronavirus Vaccine

Press Trust of India  |  New Delhi 

Covishield coronavirus vaccine | Photo: PTI
Covishield coronavirus vaccine | Photo: PTI

The has rejected Serum Institute of India's proposal seeking extension of the shelf life of Oxford-AstraZeneca COVID-19 vaccine, Covishield, from six to nine months, citing insufficient data, sources said.

The has also sought a meeting with Drugs Controller General of India (DCGI) to discuss the matter, they said.

The move comes even as India's drug regulator has extended Covishield's shelf life from six to nine months from its manufacturing date.

In a recent communique to Pune-based (SII), the has also asked the firm to formulate the doses with enough titer and/or implement a higher specification at release so that the minimum specification of= 2.5 x108ifu/dose is fulfilled throughout the shelf life.

Shelf life is the length of time for which an item remains fit for use.

The DCGI in a letter to SII in February said it has no objection in respect of 'extension of shelf life of Covishield vaccine' in multi-dose glass vial (10 dose-5ml) from six months to nine months.

"You are permitted to apply the shelf life of nine months to unlabelled vials available on hand, subject to the condition that the details of such stock, batch-wise, shall be submitted to this office and Central Drugs Laboratory, Kasauli," DCGI Dr V G Somani had said in the letter.

The DCGI's decision will help health authorities in reducing vaccine wastage.

According to an update by the UK drug regulator dated February 22, the shelf-life of the AstraZeneca COVID-19 vaccine is six months.

Meanwhile, concerns have been raised about the vaccine as the European Union's health agency concluded a "possible link" between the vaccine and rare blood clots but stressed that the benefits of the vaccine to protect against COVID-19 continue to outweigh the risks.

The UK's medicines regulator on Wednesday said that under-30s in the country will be offered an alternative to the Oxford-AstraZeneca vaccine due to "evolving evidence" linking it to rare blood clots.

Developed by Oxford University and Swedish-British pharma major AstraZeneca, Covishield is being manufactured by SII.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, April 08 2021. 19:56 IST
RECOMMENDED FOR YOU